Giao Q. Phan

UConn Health — United States

Medicine · Health Sciences

33h-index15.6kcitations92works7.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(48), Immunotherapy and Immune Responses(47), Cancer Immunotherapy and Biomarkers(32), Virus-based gene therapy research(18), Cutaneous Melanoma Detection and Management(9)

Publications92 total

MON-390 An unusual PET-avid thyroid nodule
Journal of the Endocrine Society·2025Open Access
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Journal of Clinical Oncology·2025· 11 cited
Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
Journal of Clinical Oncology·2025· 1 cited
A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism
Frontiers in Endocrinology·2025· 5 citedOpen Access
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies
American Society of Clinical Oncology Educational Book·2024· 22 cited
Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Data from CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
2023Open Access
Data from CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
2023Open Access
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplemental figure 5 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Data from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplemental figure 1 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Supplemental figure 2 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Supplemental figure 3 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
CCR Translation for This Article from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Steven A. Rosenberg(22), Marybeth S. Hughes(18), Richard M. Sherry(16), Udai S. Kammula(14), Nicholas P. Restifo(9), Mark E. Dudley(9), Kathleen E. Morton(8), Donald E. White(8), James C. Yang(8), Electron Kebebew(8), Steven K. Libutti(8), James Chih‐Hsin Yang(7), Seth M. Steinberg(7), Naris Nilubol(7), Carolyn M. Laurençot(6), Steven A. Feldman(6), Sharon Mavroukakis(5), James N. Kochenderfer(4), Suzanne L. Topalian(4), Peter Attia(4)